Clinical experiences of guided tapering of antipsychotics for patients with schizophrenia– a case series
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Clinical experiences of guided tapering of antipsychotics for patients with schizophrenia– a case series ; volume:24 ; number:1 ; day:29 ; month:3 ; year:2024 ; pages:1-8 ; date:12.2024
BMC psychiatry ; 24, Heft 1 (29.3.2024), 1-8, 12.2024
- Urheber
-
Mølgaard, Sofie Norlin
Nielsen, Mette Ødegaard
Roed, Kickan
Nielsen, Jimmi
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12888-024-05699-y
- URN
-
urn:nbn:de:101:1-2406170944599.753579357083
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:58 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Mølgaard, Sofie Norlin
- Nielsen, Mette Ødegaard
- Roed, Kickan
- Nielsen, Jimmi
- SpringerLink (Online service)
Ähnliche Objekte (12)
Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses
Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses
Can Antipsychotics Improve Social Cognition in Patients with Schizophrenia?
The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
Serum prolactin levels and sexual dysfunction in patients with schizophrenia treated with antipsychotics: comparison between aripiprazole and other atypical antipsychotics
Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia
Which first-generation antipsychotics should be “repurposed” for the treatment of schizophrenia
A study of antioxidant activity in patients with schizophrenia taking atypical antipsychotics
Current antipsychotics
Atypical antipsychotics
The interplay between vitamin D, exposure of anticholinergic antipsychotics and cognition in schizophrenia
Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses
Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses
Can Antipsychotics Improve Social Cognition in Patients with Schizophrenia?
The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
Serum prolactin levels and sexual dysfunction in patients with schizophrenia treated with antipsychotics: comparison between aripiprazole and other atypical antipsychotics
Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia
Which first-generation antipsychotics should be “repurposed” for the treatment of schizophrenia
A study of antioxidant activity in patients with schizophrenia taking atypical antipsychotics
Current antipsychotics
Atypical antipsychotics
The interplay between vitamin D, exposure of anticholinergic antipsychotics and cognition in schizophrenia
Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses
Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses
Can Antipsychotics Improve Social Cognition in Patients with Schizophrenia?
The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
Serum prolactin levels and sexual dysfunction in patients with schizophrenia treated with antipsychotics: comparison between aripiprazole and other atypical antipsychotics
Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia
Which first-generation antipsychotics should be “repurposed” for the treatment of schizophrenia
A study of antioxidant activity in patients with schizophrenia taking atypical antipsychotics
Current antipsychotics
Atypical antipsychotics